These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12714270)

  • 41. Mitochondrial Sirt3 contributes to the bone loss caused by aging or estrogen deficiency.
    Ling W; Krager K; Richardson KK; Warren AD; Ponte F; Aykin-Burns N; Manolagas SC; Almeida M; Kim HN
    JCI Insight; 2021 May; 6(10):. PubMed ID: 33878033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Catechins and osteoporosis.
    Das UN
    Nutrition; 2013 Apr; 29(4):697-9. PubMed ID: 23290097
    [No Abstract]   [Full Text] [Related]  

  • 43. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
    Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
    J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Osteoblast-induced osteoclast apoptosis by fas ligand/FAS pathway is required for maintenance of bone mass.
    Wang L; Liu S; Zhao Y; Liu D; Liu Y; Chen C; Karray S; Shi S; Jin Y
    Cell Death Differ; 2015 Oct; 22(10):1654-64. PubMed ID: 25744024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Osteoporosis from the point of view of the clinical endocrinologist.
    Szũcs J
    Agents Actions; 1994 Mar; 41(1-2):80-3. PubMed ID: 8079825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro.
    Sato T; Watanabe K; Masuhara M; Hada N; Hakeda Y
    J Bone Miner Metab; 2007; 25(1):19-27. PubMed ID: 17187190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conditioned medium of estrogen-treated osteoblasts inhibits osteoclast maturation and function in vitro.
    Qu Q; Härkönen PL; Mönkkönen J; Väänänen HK
    Bone; 1999 Aug; 25(2):211-5. PubMed ID: 10456387
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgens and bone.
    Vanderschueren D; Vandenput L; Boonen S; Lindberg MK; Bouillon R; Ohlsson C
    Endocr Rev; 2004 Jun; 25(3):389-425. PubMed ID: 15180950
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Role of Macrophage in the Pathogenesis of Osteoporosis.
    Yang DH; Yang MY
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035384
    [TBL] [Abstract][Full Text] [Related]  

  • 51. T-cells and B-cells in osteoporosis.
    Weitzmann MN
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):461-7. PubMed ID: 25191854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Skeletal receptors for steroid-family regulating glycoprotein hormones: A multilevel, integrated physiological control system.
    Blair HC; Robinson LJ; Sun L; Isales C; Davies TF; Zaidi M
    Ann N Y Acad Sci; 2011 Dec; 1240():26-31. PubMed ID: 22172036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton.
    Spelsberg TC; Subramaniam M; Riggs BL; Khosla S
    Mol Endocrinol; 1999 Jun; 13(6):819-28. PubMed ID: 10379881
    [No Abstract]   [Full Text] [Related]  

  • 54. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
    Cai X; Xing J; Long CL; Peng Q; Humphrey MB
    J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TNF-α suppresses osteogenic differentiation of MSCs by accelerating P2Y
    Du D; Zhou Z; Zhu L; Hu X; Lu J; Shi C; Chen F; Chen A
    Bone; 2018 Dec; 117():161-170. PubMed ID: 30236554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fat's loss is bone's gain.
    Pei L; Tontonoz P
    J Clin Invest; 2004 Mar; 113(6):805-6. PubMed ID: 15067310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis.
    Satpathy S; Patra A; Ahirwar B
    J Complement Integr Med; 2015 Dec; 12(4):251-66. PubMed ID: 26215536
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunologic aspects of osteoporosis.
    Ershler WB; Harman SM; Keller ET
    Dev Comp Immunol; 1997; 21(6):487-99. PubMed ID: 9463782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Bone metabolism by sex hormones and gonadotropins].
    Imai Y
    Clin Calcium; 2014 Jun; 24(6):815-9. PubMed ID: 24870831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.